|
Evaluation of pathologic and genomic characteristics in male breast cancer (MBC) patients. |
|
|
Employment - Cancer Treament Centers of America |
|
|
Employment - Cancer Treament Centers of America |
Leadership - Cancer Treament Centers of America |
|
|
Employment - Cancer Treament Centers of America |
|
|
No Relationships to Disclose |
|
|
Employment - Cancer Treament Centers of America |
|
|
Employment - Cancer Treament Centers of America |
Leadership - Cancer Treament Centers of America |
Travel, Accommodations, Expenses - Cancer Treament Centers of America |
|
|
Consulting or Advisory Role - Foundation Medicine |
|
|
Employment - Cancer Treament Centers of America |
|
|
No Relationships to Disclose |
|
|
Employment - Cancer Treament Centers of America |
Travel, Accommodations, Expenses - Cancer Treament Centers of America |
|
|
No Relationships to Disclose |
|
|
Employment - Cancer Treament Centers of America |
Consulting or Advisory Role - Amgen; Celgene; Clovis Oncology; CritiTech; Merck; Myriad Genetics; Pfizer |
Speakers' Bureau - AstraZeneca; Clovis Oncology; Genentech/Roche; Tesaro |
Expert Testimony - ACORN Research; Apotex; Dr. Reddy's Laboratories; Emcure; Fresenius Kabi; Hikma Pharmaceuticals; Hospira; Pharma International; Sagent; Strides Arcolab; Sun Pharma; Teva; Wockhardt Pharmaceuticals |
|
|
Employment - Cancer Treament Centers of America |
Leadership - Cancer Treament Centers of America; Cancer Treament Centers of America |
Consulting or Advisory Role - Eisai; Pfizer; Puma Biotechnology; R-Pharm |
Speakers' Bureau - Eisai; Pfizer |
Other Relationship - Eisai; Pfizer; Puma Biotechnology |